Intimation of order received from Customs, Excise and Service Tax Appellate Tribunal, Chennai.
Awaiting price reaction for this filing.
Aurobindo Pharma received an order from CESTAT Chennai on June 6, 2025, rejecting its appeal against a 2015 customs order. The original demand relates to alleged non-fulfilment of export obligations under two Advance Authorizations. Disputed amounts are Customs Duty of Rs. 29.17 lakhs with interest, a redemption fine of Rs. 50 lakhs, and a penalty of Rs. 10 lakhs, totaling roughly Rs. 89 lakhs. The company argued substantial compliance and had sought an extension from DGFT, which was not considered. Aurobindo plans to file a further appeal in the High Court against the CESTAT order. The company has stated there is no material impact on its financials or operations from this ruling.
The financial impact is small (around Rs. 89 lakhs) and the company says it is not material, but the case reflects ongoing tax-related litigation. The stock is unlikely to see a significant reaction, though investors should track the High Court appeal outcome.